NASDAQ:XFOR X4 Pharmaceuticals (XFOR) Stock Price, News & Analysis $2.45 -0.15 (-5.77%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$2.49 +0.04 (+1.67%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About X4 Pharmaceuticals Stock (NASDAQ:XFOR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get X4 Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.43▼$2.5550-Day Range$2.45▼$4.6452-Week Range$2.43▼$4.83Volume705,744 shsAverage Volume969,189 shsMarket Capitalization$242.91 millionP/E RatioN/ADividend YieldN/APrice Target$11.25Consensus RatingModerate Buy Company Overview X4 Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by immune and hematologic dysfunction. The company’s research centers on the CXCR4 biological pathway, which regulates the movement and retention of certain immune cells in the bone marrow and other tissues. X4’s primary product is XOLREMDI (mavorixafor), an oral CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for use in people aged 12 and older with WHIM syndrome. WHIM syndrome is a rare, inherited immunodeficiency that can cause chronic neutropenia, lymphopenia and recurrent infections. XOLREMDI is designed to increase the number of circulating neutrophils and lymphocytes, potentially helping reduce infection-related complications. Founded in 2014 and headquartered in Boston, Massachusetts, X4 Pharmaceuticals has historically focused on rare immunological and hematological disorders with significant unmet medical needs. In addition to its commercial efforts for XOLREMDI in the United States, the company has evaluated mavorixafor in other forms of chronic neutropenia and related conditions. X4 Pharmaceuticals trades on the Nasdaq under the symbol XFOR.AI Generated. May Contain Errors. Read More X4 Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreXFOR MarketRank™: 2.14689637033 of 5 starsX4 Pharmaceuticals scored higher than 43% of companies evaluated by MarketBeat, and ranked 649th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingX4 Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialX4 Pharmaceuticals has a consensus price target of $11.25, representing about 359.2% upside from its current price of $2.45.Amount of Analyst CoverageX4 Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about X4 Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for X4 Pharmaceuticals are expected to decrease in the coming year, from ($0.67) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of X4 Pharmaceuticals is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of X4 Pharmaceuticals is -2.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioX4 Pharmaceuticals has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about X4 Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.74% of the float of X4 Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverX4 Pharmaceuticals has a short interest ratio ("days to cover") of 6.04.Change versus previous monthShort interest in X4 Pharmaceuticals has recently decreased by 7.85%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldX4 Pharmaceuticals does not currently pay a dividend.Dividend GrowthX4 Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.48 News SentimentX4 Pharmaceuticals has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for X4 Pharmaceuticals this week, compared to 2 articles on an average week. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, X4 Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $353,387.00 in company stock.Percentage Held by Insiders1.13% of the stock of X4 Pharmaceuticals is held by insiders.Percentage Held by Institutions72.03% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about X4 Pharmaceuticals' insider trading history. Receive XFOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XFOR Stock News HeadlinesX4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion LeadersOctober 9, 2026 | globenewswire.comX4 Pharmaceuticals Enters Up to $150 Million Term Loan FacilityOctober 8, 2026 | marketscreener.comMHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)X4 Strengthens Cash Position Ahead Of Key Phase 3 MilestonesOctober 8, 2026 | rttnews.comX4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVenturesOctober 8, 2026 | finance.yahoo.comX4 Pharmaceuticals secures up to $150M debt facilityOctober 8, 2026 | msn.comX4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVenturesOctober 8, 2026 | globenewswire.comX4 Pharmaceuticals (NASDAQ:XFOR) CFO David Kirske Sells 11,767 Shares of StockOctober 6, 2026 | insidertrades.comSee More Headlines XFOR Stock Analysis - Frequently Asked Questions How have XFOR shares performed this year? X4 Pharmaceuticals' stock was trading at $4.00 at the start of the year. Since then, XFOR stock has decreased by 38.8% and is now trading at $2.45. How were X4 Pharmaceuticals' earnings last quarter? X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued its earnings results on Thursday, August, 6th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.05. The business had revenue of $8.81 million for the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative trailing twelve-month return on equity of 63.05%. When did X4 Pharmaceuticals' stock split? X4 Pharmaceuticals shares reverse split on the morning of Monday, April 28th 2025.The 1-30 reverse split was announced on Thursday, April 24th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did X4 Pharmaceuticals IPO? X4 Pharmaceuticals (XFOR) raised $40 million in an initial public offering on Thursday, November 16th 2017. The company issued 4,000,000 shares at $10.00 per share. How do I buy shares of X4 Pharmaceuticals? Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of X4 Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that X4 Pharmaceuticals investors own include Viking Therapeutics (VKTX), NVIDIA (NVDA), Micron Technology (MU), Sorrento Therapeutics (SRNE), Tesla (TSLA), Pfizer (PFE) and Aravive (ARAV). Company Calendar Last Earnings8/06/2026Today10/14/2026Investor Day 202610/29/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 XFOR's financial health is in the Green zone, according to TradeSmith. XFOR has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XFOR CIK1501697 Webwww.x4pharma.com Phone(857) 529-8300FaxN/AEmployees45Year Founded2010Price Target and Rating Average Price Target for X4 Pharmaceuticals$11.25 High Price Target$12.00 Low Price Target$10.00 Potential Upside/Downside+359.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$79.20 million Net Margins-568.80% Pretax Margin-568.98% Return on Equity-63.05% Return on Assets-36.89% Debt Debt-to-Equity Ratio0.49 Current Ratio11.30 Quick Ratio11.02 Sales & Book Value Annual Sales$15.85 million Price / Sales15.33 Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book1.15Miscellaneous Outstanding Shares99,147,000Free Float98,027,000Market Cap$242.91 million OptionableNo Data Beta0.46 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:XFOR) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share X4 Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XFOR Stock Alerts